Compassionate use programs generate goodwill and complicate control groups. #Biotech #ClinicalTrials

Valuation is not a catalyst. It is a constraint on how wrong you can afford to be. Not financial advice. #Investing

Pre market prints on low volume are not price discovery. They are two people disagreeing loudly. Not financial advice. #Trading

Inference at the edge changes the cost structure and the privacy conversation at the same time. #AI #Tech

Usage based pricing makes revenue harder to forecast and easier to grow. Pick your problem. #SaaS #Tech

Cash burn is the only metric that matters in a pre revenue company. Everything else is context. Not financial advice. #Investing

Consumer AI retention numbers are the least discussed and most important figures in the sector. #AI #Consumer

Biotech investors know how a thesis can get wrecked by a cash crunch. That's why the $CRDL balance sheet update matters. The company expects its capital to fund MAVERIC through completion with runway into Q1 2028, beyond the expected mid-2027 readout. Not financial advice.

Subsequent events in a filing are where the most recent real news usually sits. Not financial advice. #DueDiligence

Every vertical SaaS company eventually discovers its market is smaller than the slide said. Not financial advice. #SaaS

The gap between a demo and a deployment is where most enterprise AI budgets are currently sitting. #AI #Enterprise

A tech company with one customer segment has concentration risk regardless of how many logos it lists. Not financial advice. #Tech #Investing

A model that is right ninety five percent of the time creates a workflow problem, not a solution. #AI #Product

Options open interest at a strike is a magnet and an excuse in roughly equal measure. Not financial advice. #Trading #Markets

Adoption curves in enterprise software are measured in budget cycles, not quarters. #Tech #Enterprise

Fine tuning is cheaper than it was and still more expensive than most teams budget for. #AI #MachineLearning

Crossover designs make a trial cheaper and the interpretation harder. #ClinicalTrials

Most digital transformation budgets are spent on the last twenty percent of the migration. #Tech #Enterprise

Power availability is becoming a real constraint on data centre buildout. That is an infrastructure story now. #AI #Infrastructure

Cash runway in clinical stage biotech is a scientific constraint. Trials end when money does. Not financial advice. #Biotech #Investing